Amicus Pompe Disease Combo’s Approvability In Question As Key Trial Misses Mark
Company Touts ‘Totality Of Data’ As Supporting Approval
Amicus' Phase III study of AT-GAA in Pompe disease failed to meet its primary endpoint, raising questions about the combination's approval prospects. • Source: Shutterstock
